Arizona Tribune - SOHM Inc. Welcomes Dr. Larissa Karnaoukhova as New Vice President of Operations

David Aguilar, COO of SOHM Inc., warmly welcomes Larissa to the leadership team. "Larissa brings a wealth of expertise and a proven track record in managing complex operations and achieving key performance indicators. Her dynamic leadership style and commitment to excellence align perfectly with our mission to deliver high-quality products and services to our clients," Aguilar stated.

Larissa has held prominent roles, including Senior Director of Operations at Universal Sequencing Technology, where she successfully oversaw manufacturing, quality control, and supply chain management. Her background also includes significant achievements in project management, customer engagement, and quality assurance across various organizations, including AutoGenomics and LumiraDx, Nucleus Biologics and Invitrogen/Life Technologies. At SOHM, she will lead in further development of QA/QC, FDA audits, process validations, SOPs and other quality initiatives.

"I am excited to join SOHM Inc. and collaborate with a talented team dedicated to innovation and quality," said Larissa. "Together, we will strive to enhance our operational capabilities, improve customer satisfaction, and drive the company's growth in the health sciences sector."

Her academic credentials, including an MBA and a Ph.D. in Molecular Biology, complement her extensive professional background, providing a strong foundation for her new role. With her strategic mindset and technical expertise, Larissa is set to lead SOHM's operations into a new era of efficiency and quality.

About SOHM, Inc.:

SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted solutions for gene editing. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.

For further information regarding this announcement or to explore potential collaborations, please contact:

SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: [email protected]
Phone: (714) 522-6700

Safe Harbor Statement:

This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.

SOURCE: SOHM, Inc.

View the original press release on ACCESS Newswire

M.Robinson--AT